Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Last trade$14.14
Day change-$0.97 (-6.42%)
Day range$13.92 – $15.74
Volume5,115,196
Market cap$5.30B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.3B
Price / earnings
—
Price / book
5.78×
Price / sales
—
EV / sales
—
EV / EBITDA
-15.96×
Profitability
Earnings per share
-$0.88
Return on assets
-30.83%
Return on equity
-33.59%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.89×
Quick ratio
14.89×
Cash ratio
2.7×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$109.24M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ERAS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$12.33M
$11.72M
$10.65M
$9.36M
$10.07M
$9.46M
$9.66M
$9.59M
Research and development
$47.2M
$35.9M
$177.27M
$23.24M
$24.47M
$28.67M
$25.97M
$26.12M
Total operating expenses
$59.52M
$47.62M
$187.91M
$32.6M
$34.55M
$38.13M
$35.63M
$35.71M
Operating income
-$59.52M
-$47.62M
-$187.91M
-$32.6M
-$34.55M
-$38.13M
-$35.63M
-$35.71M
Interest expense
$8.26M
$0
$4.45M
$0
$3.97M
$0
$4.74M
$0
Income before taxes
-$51.33M
-$44.08M
-$183.44M
-$29.09M
-$30.61M
-$33.88M
-$30.97M
-$32.23M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$51.33M
-$44.08M
-$183.44M
-$29.09M
-$30.61M
-$33.88M
-$30.97M
-$32.23M
Net income attributable to common shareholders
-$51.33M
-$44.08M
-$183.44M
-$29.09M
-$30.61M
-$33.88M
-$30.97M
-$32.23M
EBITDA
-$58.81M
-$46.9M
-$187.19M
-$31.86M
-$33.79M
-$37.34M
-$34.81M
-$34.88M
Basic earnings per share
-$0.15
-$0.14
-$0.60
-$0.10
-$0.11
-$0.12
-$0.11
-$0.11
Diluted earnings per share
-$0.15
-$0.14
-$0.60
-$0.10
-$0.11
-$0.12
-$0.11
-$0.11
Recent news
Company coverage with links to the original publishers.
Pomerantz LLP is investigating Erasca, Inc. for potential securities fraud following the announced termination of Chief Operating Officer Nicholas Chetwyn on October 16, 2026. The announcement triggered a 9.95% stock price decline, falling $1.48 per share to $13.39. The company attributed the termination to realigning leadership to support RAS-targeting programs development.
Grabar Law Office has launched multiple shareholder investigations into four public companies for alleged securities fraud and breach of fiduciary duties. Erasca is accused of making misleading statements about its ERAS-0015 drug candidate and failing to disclose patent infringement risks from Revolution Medicines. Planet Fitness faces allegations of false marketing claims and concealing declining customer acquisition metrics. PROCEPT BioRobotics is investigated for undisclosed discount programs that artificially inflated sales figures and created excess inventory. The Simply Good Foods Company is accused of failing to disclose operational failures and margin erosion related to its OWYN acquisition.
Pomerantz LLP is investigating Erasca, Inc. for potential securities fraud following the announcement of Chief Operating Officer Nicholas Chetwyn's termination effective November 2, 2026. The company attributed the departure to realigning leadership for RAS-targeting programs. Erasca's stock price fell 9.95% ($1.48 per share) to $13.39 on October 16, 2026, following the disclosure.
Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.
Law firm Bernstein Liebhard announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. The firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. Current shareholders who purchased shares before November 25, 2025 are encouraged to contact the firm regarding their legal rights.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.